New And Special Drugs
-
Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
-
Lukeda (Rocbrutinib) – MCL | HongKong DengYue Medicine
-
Epkinly (Epcoritamab) – Follicular Lymphoma | HongKong DengYue Medicine
-
Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
-
Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
-
Foundayo(Orforglipron) – Obesity/Overweight | HongKong DengYue Medicine
-
Exdensur (Depemokimab) – Eosinophilic Asthma | HongKong DengYue Medicine
-
Zometa (Zoledronic Acid) – HCM | HongKong DengYue Medicine
What Can We Offer You?
Generic drugs
Dedicated to providing high-quality, affordable medicines around the world
Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage
brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability
Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs
non-prescription drugs
Flagship OTC brand - approved and accepted by global standards
Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.
Complete Guide to Cancer Treatment in China for International Patients
A cancer diagnosis often brings many important questions.Which treatment option is most suitable? Which hospital has the right expertise? Should patients consider seeking further treatment
Top 10 Hospitals in China for International Patients
Key Takeaways International Medical Services: More major Chinese hospitals have established international medical centers, with some holding JCI accreditation and offering English-speaking doctors and international
2026 Gastric Cancer Treatment Drug Guide: Latest Dual-Target Therapies, 12 Approved Treatments, and 5 Emerging Technologies
Since the beginning of 2026, the field of gastric cancer treatment has witnessed a major breakthrough. China’s National Medical Products Administration (NMPA) approved Retlirafusp Alfa
China Innovative Drug Approvals April 2026: 6 Approved, 5 by Chinese Companies
April 2026 marked another milestone for China innovative drug approvals April 2026, as the country witnessed a new wave of regulatory clearances across oncology, hematology,
Drug Shortages by Country Causes and Supply Chain Solutions
From emergency medicines to chronic disease treatments, from anti-infectives to oncology therapies, instability in the global pharmaceutical supply chain is increasingly affecting healthcare systems worldwide.
Generic Upadacitinib Approved in China, Marking the Start of JAK Inhibitor Competition
On April 27, 2026, the National Medical Products Administration (NMPA) announced that Jiangsu Huayang Pharmaceutical’s extended-release tablets became the first generic upadacitinib approved in China
RNA Therapeutics for Cardiovascular Disease: PCSK9, Lp(a) and Next-Gen Drug Pipeline (2026)
RNA therapeutics for cardiovascular disease are emerging as a transformative strategy for long-term disease management. Unlike traditional treatments that target proteins after they are produced,
Approved Immune Checkpoint Inhibitors in China: PD-1, PD-L1, CTLA-4 and Bispecific Antibodies
Immune checkpoint inhibitors (ICIs) restore T-cell–mediated antitumor immunity by blocking key regulatory pathways such as PD-1/PD-L1 and CTLA-4, and have become a cornerstone of modern
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant
